Trial Outcomes & Findings for Monotherapy Dose Finding With BI 847325 in Solid Tumours (NCT NCT01324830)

Last Updated: 2018-12-21

Results Overview

Occurrence of dose limiting toxicity (DLT) during the first treatment cycle for the treatment Schedules A and B. Some patients excluded from Treated Set (TS) as they were not evaluable for determination of maximum tolerated dose. Thus the number of evaluable TS patients are not the same as the number of original TS patients.

Recruitment status

COMPLETED

Study phase

PHASE1

Target enrollment

69 participants

Primary outcome timeframe

3 weeks

Results posted on

2018-12-21

Participant Flow

Participant milestones

Participant milestones
Measure	Schedule A BI 847325 6 mg (A1) Schedule A BI 847325 6 mg/day group. Schedule A: 2 weeks on treatment, 1 week off treatment, repeated every 3 weeks. BI 847325 tablet(s) administered once daily in the morning 1 hour before breakfast and taken with at least 250 mL of water.	Schedule A BI 847325 9 mg (A2) Schedule A BI 847325 9 mg/day group. Schedule A: 2 weeks on treatment, 1 week off treatment, repeated every 3 weeks. BI 847325 tablet(s) administered once daily in the morning 1 hour before breakfast and taken with at least 250 mL of water.	Schedule A BI 847325 13 mg (A3) Schedule A BI 847325 13 mg/day group. Schedule A: 2 weeks on treatment, 1 week off treatment, repeated every 3 weeks. BI 847325 tablet(s) administered once daily in the morning 1 hour before breakfast and taken with at least 250 mL of water.	Schedule A BI 847325 19 mg (A4) Schedule A BI 847325 19 mg/day group. Schedule A: 2 weeks on treatment, 1 week off treatment, repeated every 3 weeks. BI 847325 tablet(s) administered once daily in the morning 1 hour before breakfast and taken with at least 250 mL of water.	Schedule A BI 847325 26 mg (A5) Schedule A BI 847325 26 mg/day group. Schedule A: 2 weeks on treatment, 1 week off treatment, repeated every 3 weeks. BI 847325 tablet(s) administered once daily in the morning 1 hour before breakfast and taken with at least 250 mL of water.	Schedule A BI 847325 33 mg (A6) Schedule A BI 847325 33 mg/day group. Schedule A: 2 weeks on treatment, 1 week off treatment, repeated every 3 weeks. BI 847325 tablet(s) administered once daily in the morning 1 hour before breakfast and taken with at least 250 mL of water.	Schedule A BI 847325 46 mg (A7) Schedule A BI 847325 46 mg/day group. Schedule A: 2 weeks on treatment, 1 week off treatment, repeated every 3 weeks. BI 847325 tablet(s) administered once daily in the morning 1 hour before breakfast and taken with at least 250 mL of water.	Schedule A BI 847325 63 mg (A8) Schedule A BI 847325 63 mg/day group. Schedule A: 2 weeks on treatment, 1 week off treatment, repeated every 3 weeks. BI 847325 tablet(s) administered once daily in the morning 1 hour before breakfast and taken with at least 250 mL of water.	Schedule A BI 847325 86 mg (A9) Schedule A BI 847325 86 mg/day group. Schedule A: 2 weeks on treatment, 1 week off treatment, repeated every 3 weeks. BI 847325 tablet(s) administered once daily in the morning 1 hour before breakfast and taken with at least 250 mL of water.	Schedule A BI 847325 120 mg (A10) Schedule A BI 847325 120 mg/day group. Schedule A: 2 weeks on treatment, 1 week off treatment, repeated every 3 weeks. BI 847325 tablet(s) administered once daily in the morning 1 hour before breakfast and taken with at least 250 mL of water.	Schedule A BI 847325 160 mg (A11) Schedule A BI 847325 160 mg/day group. Schedule A: 2 weeks on treatment, 1 week off treatment, repeated every 3 weeks. BI 847325 tablet(s) administered once daily in the morning 1 hour before breakfast and taken with at least 250 mL of water.	Schedule B BI 847325 6 mg (B1) Schedule B BI 847325 6 mg/day group. Schedule B: 5 days on treatment, 2 days off treatment, repeated every week, in 3-week cycles. BI 847325 tablet(s) administered once daily in the morning 1 hour before breakfast and taken with at least 250 mL of water.	Schedule B BI 847325 12 mg (B2) Schedule B BI 847325 12 mg/day group. Schedule B: 5 days on treatment, 2 days off treatment, repeated every week, in 3-week cycles. BI 847325 tablet(s) administered once daily in the morning 1 hour before breakfast and taken with at least 250 mL of water.	Schedule B BI 847325 23 mg (B3) Schedule B BI 847325 23 mg/day group. Schedule B: 5 days on treatment, 2 days off treatment, repeated every week, in 3-week cycles. BI 847325 tablet(s) administered once daily in the morning 1 hour before breakfast and taken with at least 250 mL of water.	Schedule B BI 847325 46 mg (B4) Schedule B BI 847325 46 mg/day group. Schedule B: 5 days on treatment, 2 days off treatment, repeated every week, in 3-week cycles. BI 847325 tablet(s) administered once daily in the morning 1 hour before breakfast and taken with at least 250 mL of water.	Schedule B BI 847325 90 mg (B5) Schedule B BI 847325 90 mg/day group. Schedule B: 5 days on treatment, 2 days off treatment, repeated every week, in 3-week cycles. BI 847325 tablet(s) administered once daily in the morning 1 hour before breakfast and taken with at least 250 mL of water.	Schedule B BI 847325 180 mg (B6) Schedule B BI 847325 180 mg/day group. Schedule B: 5 days on treatment, 2 days off treatment, repeated every week, in 3-week cycles. BI 847325 tablet(s) administered once daily in the morning 1 hour before breakfast and taken with at least 250 mL of water.	Schedule B BI 847325 130 mg (B7) Schedule B BI 847325 130 mg/day group. Schedule B: 5 days on treatment, 2 days off treatment, repeated every week, in 3-week cycles. BI 847325 tablet(s) administered once daily in the morning 1 hour before breakfast and taken with at least 250 mL of water.	Schedule B BI 847325 150 mg (B8) Schedule B BI 847325 150 mg/day group. Schedule B: 5 days on treatment, 2 days off treatment, repeated every week, in 3-week cycles. BI 847325 tablet(s) administered once daily in the morning 1 hour before breakfast and taken with at least 250 mL of water.
Overall Study STARTED	3	3	3	3	7	7	3	3	5	6	4	1	1	1	1	3	3	6	6
Overall Study COMPLETED	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Overall Study NOT COMPLETED	3	3	3	3	7	7	3	3	5	6	4	1	1	1	1	3	3	6	6

Reasons for withdrawal

Reasons for withdrawal
Measure	Schedule A BI 847325 6 mg (A1) Schedule A BI 847325 6 mg/day group. Schedule A: 2 weeks on treatment, 1 week off treatment, repeated every 3 weeks. BI 847325 tablet(s) administered once daily in the morning 1 hour before breakfast and taken with at least 250 mL of water.	Schedule A BI 847325 9 mg (A2) Schedule A BI 847325 9 mg/day group. Schedule A: 2 weeks on treatment, 1 week off treatment, repeated every 3 weeks. BI 847325 tablet(s) administered once daily in the morning 1 hour before breakfast and taken with at least 250 mL of water.	Schedule A BI 847325 13 mg (A3) Schedule A BI 847325 13 mg/day group. Schedule A: 2 weeks on treatment, 1 week off treatment, repeated every 3 weeks. BI 847325 tablet(s) administered once daily in the morning 1 hour before breakfast and taken with at least 250 mL of water.	Schedule A BI 847325 19 mg (A4) Schedule A BI 847325 19 mg/day group. Schedule A: 2 weeks on treatment, 1 week off treatment, repeated every 3 weeks. BI 847325 tablet(s) administered once daily in the morning 1 hour before breakfast and taken with at least 250 mL of water.	Schedule A BI 847325 26 mg (A5) Schedule A BI 847325 26 mg/day group. Schedule A: 2 weeks on treatment, 1 week off treatment, repeated every 3 weeks. BI 847325 tablet(s) administered once daily in the morning 1 hour before breakfast and taken with at least 250 mL of water.	Schedule A BI 847325 33 mg (A6) Schedule A BI 847325 33 mg/day group. Schedule A: 2 weeks on treatment, 1 week off treatment, repeated every 3 weeks. BI 847325 tablet(s) administered once daily in the morning 1 hour before breakfast and taken with at least 250 mL of water.	Schedule A BI 847325 46 mg (A7) Schedule A BI 847325 46 mg/day group. Schedule A: 2 weeks on treatment, 1 week off treatment, repeated every 3 weeks. BI 847325 tablet(s) administered once daily in the morning 1 hour before breakfast and taken with at least 250 mL of water.	Schedule A BI 847325 63 mg (A8) Schedule A BI 847325 63 mg/day group. Schedule A: 2 weeks on treatment, 1 week off treatment, repeated every 3 weeks. BI 847325 tablet(s) administered once daily in the morning 1 hour before breakfast and taken with at least 250 mL of water.	Schedule A BI 847325 86 mg (A9) Schedule A BI 847325 86 mg/day group. Schedule A: 2 weeks on treatment, 1 week off treatment, repeated every 3 weeks. BI 847325 tablet(s) administered once daily in the morning 1 hour before breakfast and taken with at least 250 mL of water.	Schedule A BI 847325 120 mg (A10) Schedule A BI 847325 120 mg/day group. Schedule A: 2 weeks on treatment, 1 week off treatment, repeated every 3 weeks. BI 847325 tablet(s) administered once daily in the morning 1 hour before breakfast and taken with at least 250 mL of water.	Schedule A BI 847325 160 mg (A11) Schedule A BI 847325 160 mg/day group. Schedule A: 2 weeks on treatment, 1 week off treatment, repeated every 3 weeks. BI 847325 tablet(s) administered once daily in the morning 1 hour before breakfast and taken with at least 250 mL of water.	Schedule B BI 847325 6 mg (B1) Schedule B BI 847325 6 mg/day group. Schedule B: 5 days on treatment, 2 days off treatment, repeated every week, in 3-week cycles. BI 847325 tablet(s) administered once daily in the morning 1 hour before breakfast and taken with at least 250 mL of water.	Schedule B BI 847325 12 mg (B2) Schedule B BI 847325 12 mg/day group. Schedule B: 5 days on treatment, 2 days off treatment, repeated every week, in 3-week cycles. BI 847325 tablet(s) administered once daily in the morning 1 hour before breakfast and taken with at least 250 mL of water.	Schedule B BI 847325 23 mg (B3) Schedule B BI 847325 23 mg/day group. Schedule B: 5 days on treatment, 2 days off treatment, repeated every week, in 3-week cycles. BI 847325 tablet(s) administered once daily in the morning 1 hour before breakfast and taken with at least 250 mL of water.	Schedule B BI 847325 46 mg (B4) Schedule B BI 847325 46 mg/day group. Schedule B: 5 days on treatment, 2 days off treatment, repeated every week, in 3-week cycles. BI 847325 tablet(s) administered once daily in the morning 1 hour before breakfast and taken with at least 250 mL of water.	Schedule B BI 847325 90 mg (B5) Schedule B BI 847325 90 mg/day group. Schedule B: 5 days on treatment, 2 days off treatment, repeated every week, in 3-week cycles. BI 847325 tablet(s) administered once daily in the morning 1 hour before breakfast and taken with at least 250 mL of water.	Schedule B BI 847325 180 mg (B6) Schedule B BI 847325 180 mg/day group. Schedule B: 5 days on treatment, 2 days off treatment, repeated every week, in 3-week cycles. BI 847325 tablet(s) administered once daily in the morning 1 hour before breakfast and taken with at least 250 mL of water.	Schedule B BI 847325 130 mg (B7) Schedule B BI 847325 130 mg/day group. Schedule B: 5 days on treatment, 2 days off treatment, repeated every week, in 3-week cycles. BI 847325 tablet(s) administered once daily in the morning 1 hour before breakfast and taken with at least 250 mL of water.	Schedule B BI 847325 150 mg (B8) Schedule B BI 847325 150 mg/day group. Schedule B: 5 days on treatment, 2 days off treatment, repeated every week, in 3-week cycles. BI 847325 tablet(s) administered once daily in the morning 1 hour before breakfast and taken with at least 250 mL of water.
Overall Study Progressive Disease	3	2	3	3	6	6	3	3	3	6	2	1	1	1	1	3	2	3	4
Overall Study Dose limiting toxicity	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	1	1	1
Overall Study Reason not mentioned above	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0
Overall Study Adverse Event, serious fatal	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Overall Study Adverse Event, non-fatal	0	0	0	0	0	0	0	0	2	0	1	0	0	0	0	0	0	1	0
Overall Study Withdrawal by Subject	0	0	0	0	0	1	0	0	0	0	1	0	0	0	0	0	0	0	1

Baseline Characteristics

Monotherapy Dose Finding With BI 847325 in Solid Tumours

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure	Schedule A BI 847325 6 mg (A1) n=3 Participants Schedule A BI 847325 6 mg/day group. Schedule A: 2 weeks on treatment, 1 week off treatment, repeated every 3 weeks. BI 847325 tablet(s) administered once daily in the morning 1 hour before breakfast and taken with at least 250 mL of water.	Schedule A BI 847325 9 mg (A2) n=3 Participants Schedule A BI 847325 9 mg/day group. Schedule A: 2 weeks on treatment, 1 week off treatment, repeated every 3 weeks. BI 847325 tablet(s) administered once daily in the morning 1 hour before breakfast and taken with at least 250 mL of water.	Schedule A BI 847325 13 mg (A3) n=3 Participants Schedule A BI 847325 13 mg/day group. Schedule A: 2 weeks on treatment, 1 week off treatment, repeated every 3 weeks. BI 847325 tablet(s) administered once daily in the morning 1 hour before breakfast and taken with at least 250 mL of water.	Schedule A BI 847325 19 mg (A4) n=3 Participants Schedule A BI 847325 19 mg/day group. Schedule A: 2 weeks on treatment, 1 week off treatment, repeated every 3 weeks. BI 847325 tablet(s) administered once daily in the morning 1 hour before breakfast and taken with at least 250 mL of water.	Schedule A BI 847325 26 mg (A5) n=7 Participants Schedule A BI 847325 26 mg/day group. Schedule A: 2 weeks on treatment, 1 week off treatment, repeated every 3 weeks. BI 847325 tablet(s) administered once daily in the morning 1 hour before breakfast and taken with at least 250 mL of water.	Schedule A BI 847325 33 mg (A6) n=7 Participants Schedule A BI 847325 33 mg/day group. Schedule A: 2 weeks on treatment, 1 week off treatment, repeated every 3 weeks. BI 847325 tablet(s) administered once daily in the morning 1 hour before breakfast and taken with at least 250 mL of water.	Schedule A BI 847325 46 mg (A7) n=3 Participants Schedule A BI 847325 46 mg/day group. Schedule A: 2 weeks on treatment, 1 week off treatment, repeated every 3 weeks. BI 847325 tablet(s) administered once daily in the morning 1 hour before breakfast and taken with at least 250 mL of water.	Schedule A BI 847325 63 mg (A8) n=3 Participants Schedule A BI 847325 63 mg/day group. Schedule A: 2 weeks on treatment, 1 week off treatment, repeated every 3 weeks. BI 847325 tablet(s) administered once daily in the morning 1 hour before breakfast and taken with at least 250 mL of water.	Schedule A BI 847325 86 mg (A9) n=5 Participants Schedule A BI 847325 86 mg/day group. Schedule A: 2 weeks on treatment, 1 week off treatment, repeated every 3 weeks. BI 847325 tablet(s) administered once daily in the morning 1 hour before breakfast and taken with at least 250 mL of water.	Schedule A BI 847325 120 mg (A10) n=6 Participants Schedule A BI 847325 120 mg/day group. Schedule A: 2 weeks on treatment, 1 week off treatment, repeated every 3 weeks. BI 847325 tablet(s) administered once daily in the morning 1 hour before breakfast and taken with at least 250 mL of water.	Schedule A BI 847325 160 mg (A11) n=4 Participants Schedule A BI 847325 160 mg/day group. Schedule A: 2 weeks on treatment, 1 week off treatment, repeated every 3 weeks. BI 847325 tablet(s) administered once daily in the morning 1 hour before breakfast and taken with at least 250 mL of water.	Schedule B BI 847325 6 mg (B1) n=1 Participants Schedule B BI 847325 6 mg/day group. Schedule B: 5 days on treatment, 2 days off treatment, repeated every week, in 3-week cycles. BI 847325 tablet(s) administered once daily in the morning 1 hour before breakfast and taken with at least 250 mL of water.	Schedule B BI 847325 12 mg (B2) n=1 Participants Schedule B BI 847325 12 mg/day group. Schedule B: 5 days on treatment, 2 days off treatment, repeated every week, in 3-week cycles. BI 847325 tablet(s) administered once daily in the morning 1 hour before breakfast and taken with at least 250 mL of water.	Schedule B BI 847325 23 mg (B3) n=1 Participants Schedule B BI 847325 23 mg/day group. Schedule B: 5 days on treatment, 2 days off treatment, repeated every week, in 3-week cycles. BI 847325 tablet(s) administered once daily in the morning 1 hour before breakfast and taken with at least 250 mL of water.	Schedule B BI 847325 46 mg (B4) n=1 Participants Schedule B BI 847325 46 mg/day group. Schedule B: 5 days on treatment, 2 days off treatment, repeated every week, in 3-week cycles. BI 847325 tablet(s) administered once daily in the morning 1 hour before breakfast and taken with at least 250 mL of water.	Schedule B BI 847325 90 mg (B5) n=3 Participants Schedule B BI 847325 90 mg/day group. Schedule B: 5 days on treatment, 2 days off treatment, repeated every week, in 3-week cycles. BI 847325 tablet(s) administered once daily in the morning 1 hour before breakfast and taken with at least 250 mL of water.	Schedule B BI 847325 180 mg (B6) n=3 Participants Schedule B BI 847325 180 mg/day group. Schedule B: 5 days on treatment, 2 days off treatment, repeated every week, in 3-week cycles. BI 847325 tablet(s) administered once daily in the morning 1 hour before breakfast and taken with at least 250 mL of water.	Schedule B BI 847325 130 mg (B7) n=6 Participants Schedule B BI 847325 130 mg/day group. Schedule B: 5 days on treatment, 2 days off treatment, repeated every week, in 3-week cycles. BI 847325 tablet(s) administered once daily in the morning 1 hour before breakfast and taken with at least 250 mL of water.	Schedule B BI 847325 150 mg (B8) n=6 Participants Schedule B BI 847325 150 mg/day group. Schedule B: 5 days on treatment, 2 days off treatment, repeated every week, in 3-week cycles. BI 847325 tablet(s) administered once daily in the morning 1 hour before breakfast and taken with at least 250 mL of water.	Total n=69 Participants Total of all reporting groups
Age, Continuous	58.7 Years STANDARD_DEVIATION 8.1 • n=93 Participants	62.7 Years STANDARD_DEVIATION 3.5 • n=4 Participants	58.7 Years STANDARD_DEVIATION 4.2 • n=27 Participants	57.7 Years STANDARD_DEVIATION 12.2 • n=483 Participants	58.9 Years STANDARD_DEVIATION 9.8 • n=36 Participants	55.3 Years STANDARD_DEVIATION 14.1 • n=10 Participants	66 Years STANDARD_DEVIATION 10.4 • n=115 Participants	55.3 Years STANDARD_DEVIATION 5.1 • n=40 Participants	58.6 Years STANDARD_DEVIATION 9.9 • n=8 Participants	59.3 Years STANDARD_DEVIATION 8.2 • n=62 Participants	55 Years STANDARD_DEVIATION 7.4 • n=95 Participants	60 Years STANDARD_DEVIATION 0 • n=129 Participants	49 Years STANDARD_DEVIATION 0 • n=36 Participants	44 Years STANDARD_DEVIATION 0 • n=36 Participants	62 Years STANDARD_DEVIATION 0 • n=24 Participants	49.3 Years STANDARD_DEVIATION 15.3 • n=135 Participants	42.7 Years STANDARD_DEVIATION 3.5 • n=136 Participants	62.2 Years STANDARD_DEVIATION 13.5 • n=44 Participants	51.7 Years STANDARD_DEVIATION 13.4 • n=667 Participants	56.8 Years STANDARD_DEVIATION 10.6 • n=7 Participants
Sex: Female, Male Female	2 Participants n=93 Participants	3 Participants n=4 Participants	1 Participants n=27 Participants	1 Participants n=483 Participants	5 Participants n=36 Participants	3 Participants n=10 Participants	2 Participants n=115 Participants	0 Participants n=40 Participants	3 Participants n=8 Participants	1 Participants n=62 Participants	3 Participants n=95 Participants	0 Participants n=129 Participants	1 Participants n=36 Participants	0 Participants n=36 Participants	1 Participants n=24 Participants	1 Participants n=135 Participants	2 Participants n=136 Participants	3 Participants n=44 Participants	4 Participants n=667 Participants	36 Participants n=7 Participants
Sex: Female, Male Male	1 Participants n=93 Participants	0 Participants n=4 Participants	2 Participants n=27 Participants	2 Participants n=483 Participants	2 Participants n=36 Participants	4 Participants n=10 Participants	1 Participants n=115 Participants	3 Participants n=40 Participants	2 Participants n=8 Participants	5 Participants n=62 Participants	1 Participants n=95 Participants	1 Participants n=129 Participants	0 Participants n=36 Participants	1 Participants n=36 Participants	0 Participants n=24 Participants	2 Participants n=135 Participants	1 Participants n=136 Participants	3 Participants n=44 Participants	2 Participants n=667 Participants	33 Participants n=7 Participants

PRIMARY outcome

Timeframe: 3 weeks

Population: Treated Set (TS)

Outcome measures

Outcome measures
Measure	Schedule A BI 847325 6 mg (A1) n=3 Participants Schedule A BI 847325 6 mg/day group. Schedule A: 2 weeks on treatment, 1 week off treatment, repeated every 3 weeks. BI 847325 tablet(s) administered once daily in the morning 1 hour before breakfast and taken with at least 250 mL of water.	Schedule A BI 847325 9 mg (A2) n=3 Participants Schedule A BI 847325 9 mg/day group. Schedule A: 2 weeks on treatment, 1 week off treatment, repeated every 3 weeks. BI 847325 tablet(s) administered once daily in the morning 1 hour before breakfast and taken with at least 250 mL of water.	Schedule A BI 847325 13 mg (A3) n=3 Participants Schedule A BI 847325 13 mg/day group. Schedule A: 2 weeks on treatment, 1 week off treatment, repeated every 3 weeks. BI 847325 tablet(s) administered once daily in the morning 1 hour before breakfast and taken with at least 250 mL of water.	Schedule A BI 847325 19 mg (A4) n=3 Participants Schedule A BI 847325 19 mg/day group. Schedule A: 2 weeks on treatment, 1 week off treatment, repeated every 3 weeks. BI 847325 tablet(s) administered once daily in the morning 1 hour before breakfast and taken with at least 250 mL of water.	Schedule A BI 847325 26 mg (A5) n=6 Participants Schedule A BI 847325 26 mg/day group. Schedule A: 2 weeks on treatment, 1 week off treatment, repeated every 3 weeks. BI 847325 tablet(s) administered once daily in the morning 1 hour before breakfast and taken with at least 250 mL of water.	Schedule A BI 847325 33 mg (A6) n=6 Participants Schedule A BI 847325 33 mg/day group. Schedule A: 2 weeks on treatment, 1 week off treatment, repeated every 3 weeks. BI 847325 tablet(s) administered once daily in the morning 1 hour before breakfast and taken with at least 250 mL of water.	Schedule A BI 847325 46 mg (A7) n=3 Participants Schedule A BI 847325 46 mg/day group. Schedule A: 2 weeks on treatment, 1 week off treatment, repeated every 3 weeks. BI 847325 tablet(s) administered once daily in the morning 1 hour before breakfast and taken with at least 250 mL of water.	Schedule A BI 847325 63 mg (A8) n=3 Participants Schedule A BI 847325 63 mg/day group. Schedule A: 2 weeks on treatment, 1 week off treatment, repeated every 3 weeks. BI 847325 tablet(s) administered once daily in the morning 1 hour before breakfast and taken with at least 250 mL of water.	Schedule A BI 847325 86 mg (A9) n=3 Participants Schedule A BI 847325 86 mg/day group. Schedule A: 2 weeks on treatment, 1 week off treatment, repeated every 3 weeks. BI 847325 tablet(s) administered once daily in the morning 1 hour before breakfast and taken with at least 250 mL of water.	Schedule A BI 847325 120 mg (A10) n=6 Participants Schedule A BI 847325 120 mg/day group. Schedule A: 2 weeks on treatment, 1 week off treatment, repeated every 3 weeks. BI 847325 tablet(s) administered once daily in the morning 1 hour before breakfast and taken with at least 250 mL of water.	Schedule A BI 847325 160 mg (A11) n=3 Participants Schedule A BI 847325 160 mg/day group. Schedule A: 2 weeks on treatment, 1 week off treatment, repeated every 3 weeks. BI 847325 tablet(s) administered once daily in the morning 1 hour before breakfast and taken with at least 250 mL of water.	Schedule B BI 847325 6 mg (B1) n=1 Participants Schedule B BI 847325 6 mg/day group. Schedule B: 5 days on treatment, 2 days off treatment, repeated every week, in 3-week cycles. BI 847325 tablet(s) administered once daily in the morning 1 hour before breakfast and taken with at least 250 mL of water.	Schedule B BI 847325 12 mg (B2) n=1 Participants Schedule B BI 847325 12 mg/day group. Schedule B: 5 days on treatment, 2 days off treatment, repeated every week, in 3-week cycles. BI 847325 tablet(s) administered once daily in the morning 1 hour before breakfast and taken with at least 250 mL of water.	Schedule B BI 847325 23 mg (B3) n=1 Participants Schedule B BI 847325 23 mg/day group. Schedule B: 5 days on treatment, 2 days off treatment, repeated every week, in 3-week cycles. BI 847325 tablet(s) administered once daily in the morning 1 hour before breakfast and taken with at least 250 mL of water.	Schedule B BI 847325 46 mg (B4) n=1 Participants Schedule B BI 847325 46 mg/day group. Schedule B: 5 days on treatment, 2 days off treatment, repeated every week, in 3-week cycles. BI 847325 tablet(s) administered once daily in the morning 1 hour before breakfast and taken with at least 250 mL of water.	Schedule B BI 847325 90 mg (B5) n=3 Participants Schedule B BI 847325 90 mg/day group. Schedule B: 5 days on treatment, 2 days off treatment, repeated every week, in 3-week cycles. BI 847325 tablet(s) administered once daily in the morning 1 hour before breakfast and taken with at least 250 mL of water.	Schedule B BI 847325 180 mg (B6) n=3 Participants Schedule B BI 847325 180 mg/day group. Schedule B: 5 days on treatment, 2 days off treatment, repeated every week, in 3-week cycles. BI 847325 tablet(s) administered once daily in the morning 1 hour before breakfast and taken with at least 250 mL of water.	Schedule B BI 847325 130 mg (B7) n=6 Participants Schedule B BI 847325 130 mg/day group. Schedule B: 5 days on treatment, 2 days off treatment, repeated every week, in 3-week cycles. BI 847325 tablet(s) administered once daily in the morning 1 hour before breakfast and taken with at least 250 mL of water.	Schedule B BI 847325 150 mg (B8) n=6 Participants Schedule B BI 847325 150 mg/day group. Schedule B: 5 days on treatment, 2 days off treatment, repeated every week, in 3-week cycles. BI 847325 tablet(s) administered once daily in the morning 1 hour before breakfast and taken with at least 250 mL of water.	Schedule A Total (Total A) n=42 Participants All patients with schedule A. Schedule A: 2 weeks on treatment, 1 week off treatment, repeated every 3 weeks.	Schedule B Total (Total B) n=22 Participants Schedule B total treated patients. Schedule B: 5 days on treatment, 2 days off treatment, repeated every week, in 3-week cycles.	Total Patients n=64 Participants Schedule A and B total patients.
Percentage of Patients With Dose Limiting Toxicity During the First Treatment Cycle in Phase Ia Part of the Study	0 Percentage of participants	0 Percentage of participants	0 Percentage of participants	0 Percentage of participants	16.7 Percentage of participants	16.7 Percentage of participants	0 Percentage of participants	0 Percentage of participants	0 Percentage of participants	16.7 Percentage of participants	66.7 Percentage of participants	0 Percentage of participants	0 Percentage of participants	0 Percentage of participants	0 Percentage of participants	0 Percentage of participants	66.7 Percentage of participants	16.7 Percentage of participants	16.7 Percentage of participants	11.9 Percentage of participants	18.2 Percentage of participants	14.1 Percentage of participants

SECONDARY outcome

Timeframe: From the start of treatment until the last evaluable assessment. The data cut-off date is 29-Nov-2013

Population: TS

Best overall response was the best response a patient experienced during their time on study from the start of treatment until: disease progression, the last evaluable assessment in the absence of progression, or the start of subsequent anti-cancer therapy. Death was not considered as progressive disease when determining best overall response; patients who died prior to an evaluable imaging assessment were reported as not evaluable. Some patients were excluded from TS as they were not evaluable for determination of maximum tolerated dose. Thus the number of evaluable TS patients are not the same as the number of original TS patients.

Outcome measures

Outcome measures
Measure	Schedule A BI 847325 6 mg (A1) n=3 Participants Schedule A BI 847325 6 mg/day group. Schedule A: 2 weeks on treatment, 1 week off treatment, repeated every 3 weeks. BI 847325 tablet(s) administered once daily in the morning 1 hour before breakfast and taken with at least 250 mL of water.	Schedule A BI 847325 9 mg (A2) n=2 Participants Schedule A BI 847325 9 mg/day group. Schedule A: 2 weeks on treatment, 1 week off treatment, repeated every 3 weeks. BI 847325 tablet(s) administered once daily in the morning 1 hour before breakfast and taken with at least 250 mL of water.	Schedule A BI 847325 13 mg (A3) n=3 Participants Schedule A BI 847325 13 mg/day group. Schedule A: 2 weeks on treatment, 1 week off treatment, repeated every 3 weeks. BI 847325 tablet(s) administered once daily in the morning 1 hour before breakfast and taken with at least 250 mL of water.	Schedule A BI 847325 19 mg (A4) n=3 Participants Schedule A BI 847325 19 mg/day group. Schedule A: 2 weeks on treatment, 1 week off treatment, repeated every 3 weeks. BI 847325 tablet(s) administered once daily in the morning 1 hour before breakfast and taken with at least 250 mL of water.	Schedule A BI 847325 26 mg (A5) n=7 Participants Schedule A BI 847325 26 mg/day group. Schedule A: 2 weeks on treatment, 1 week off treatment, repeated every 3 weeks. BI 847325 tablet(s) administered once daily in the morning 1 hour before breakfast and taken with at least 250 mL of water.	Schedule A BI 847325 33 mg (A6) n=7 Participants Schedule A BI 847325 33 mg/day group. Schedule A: 2 weeks on treatment, 1 week off treatment, repeated every 3 weeks. BI 847325 tablet(s) administered once daily in the morning 1 hour before breakfast and taken with at least 250 mL of water.	Schedule A BI 847325 46 mg (A7) n=3 Participants Schedule A BI 847325 46 mg/day group. Schedule A: 2 weeks on treatment, 1 week off treatment, repeated every 3 weeks. BI 847325 tablet(s) administered once daily in the morning 1 hour before breakfast and taken with at least 250 mL of water.	Schedule A BI 847325 63 mg (A8) n=3 Participants Schedule A BI 847325 63 mg/day group. Schedule A: 2 weeks on treatment, 1 week off treatment, repeated every 3 weeks. BI 847325 tablet(s) administered once daily in the morning 1 hour before breakfast and taken with at least 250 mL of water.	Schedule A BI 847325 86 mg (A9) n=5 Participants Schedule A BI 847325 86 mg/day group. Schedule A: 2 weeks on treatment, 1 week off treatment, repeated every 3 weeks. BI 847325 tablet(s) administered once daily in the morning 1 hour before breakfast and taken with at least 250 mL of water.	Schedule A BI 847325 120 mg (A10) n=6 Participants Schedule A BI 847325 120 mg/day group. Schedule A: 2 weeks on treatment, 1 week off treatment, repeated every 3 weeks. BI 847325 tablet(s) administered once daily in the morning 1 hour before breakfast and taken with at least 250 mL of water.	Schedule A BI 847325 160 mg (A11) n=4 Participants Schedule A BI 847325 160 mg/day group. Schedule A: 2 weeks on treatment, 1 week off treatment, repeated every 3 weeks. BI 847325 tablet(s) administered once daily in the morning 1 hour before breakfast and taken with at least 250 mL of water.	Schedule B BI 847325 6 mg (B1) n=1 Participants Schedule B BI 847325 6 mg/day group. Schedule B: 5 days on treatment, 2 days off treatment, repeated every week, in 3-week cycles. BI 847325 tablet(s) administered once daily in the morning 1 hour before breakfast and taken with at least 250 mL of water.	Schedule B BI 847325 12 mg (B2) n=1 Participants Schedule B BI 847325 12 mg/day group. Schedule B: 5 days on treatment, 2 days off treatment, repeated every week, in 3-week cycles. BI 847325 tablet(s) administered once daily in the morning 1 hour before breakfast and taken with at least 250 mL of water.	Schedule B BI 847325 23 mg (B3) n=1 Participants Schedule B BI 847325 23 mg/day group. Schedule B: 5 days on treatment, 2 days off treatment, repeated every week, in 3-week cycles. BI 847325 tablet(s) administered once daily in the morning 1 hour before breakfast and taken with at least 250 mL of water.	Schedule B BI 847325 46 mg (B4) n=1 Participants Schedule B BI 847325 46 mg/day group. Schedule B: 5 days on treatment, 2 days off treatment, repeated every week, in 3-week cycles. BI 847325 tablet(s) administered once daily in the morning 1 hour before breakfast and taken with at least 250 mL of water.	Schedule B BI 847325 90 mg (B5) n=3 Participants Schedule B BI 847325 90 mg/day group. Schedule B: 5 days on treatment, 2 days off treatment, repeated every week, in 3-week cycles. BI 847325 tablet(s) administered once daily in the morning 1 hour before breakfast and taken with at least 250 mL of water.	Schedule B BI 847325 180 mg (B6) n=3 Participants Schedule B BI 847325 180 mg/day group. Schedule B: 5 days on treatment, 2 days off treatment, repeated every week, in 3-week cycles. BI 847325 tablet(s) administered once daily in the morning 1 hour before breakfast and taken with at least 250 mL of water.	Schedule B BI 847325 130 mg (B7) n=6 Participants Schedule B BI 847325 130 mg/day group. Schedule B: 5 days on treatment, 2 days off treatment, repeated every week, in 3-week cycles. BI 847325 tablet(s) administered once daily in the morning 1 hour before breakfast and taken with at least 250 mL of water.	Schedule B BI 847325 150 mg (B8) n=6 Participants Schedule B BI 847325 150 mg/day group. Schedule B: 5 days on treatment, 2 days off treatment, repeated every week, in 3-week cycles. BI 847325 tablet(s) administered once daily in the morning 1 hour before breakfast and taken with at least 250 mL of water.	Schedule A Total (Total A) n=47 Participants All patients with schedule A. Schedule A: 2 weeks on treatment, 1 week off treatment, repeated every 3 weeks.	Schedule B Total (Total B) n=22 Participants Schedule B total treated patients. Schedule B: 5 days on treatment, 2 days off treatment, repeated every week, in 3-week cycles.	Total Patients n=69 Participants Schedule A and B total patients.
Best Overall Response complete response	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants
Best Overall Response partial response	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	1 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	1 Participants	0 Participants	1 Participants
Best Overall Response not evaluable	0 Participants	1 Participants	0 Participants	0 Participants	2 Participants	2 Participants	0 Participants	1 Participants	2 Participants	1 Participants	2 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	1 Participants	1 Participants	0 Participants	11 Participants	2 Participants	13 Participants
Best Overall Response stable disease	0 Participants	0 Participants	1 Participants	1 Participants	3 Participants	1 Participants	0 Participants	1 Participants	1 Participants	2 Participants	1 Participants	0 Participants	0 Participants	0 Participants	0 Participants	2 Participants	2 Participants	4 Participants	2 Participants	11 Participants	10 Participants	21 Participants
Best Overall Response progressive disease	3 Participants	2 Participants	2 Participants	2 Participants	2 Participants	4 Participants	3 Participants	1 Participants	2 Participants	3 Participants	0 Participants	1 Participants	1 Participants	1 Participants	1 Participants	1 Participants	0 Participants	1 Participants	4 Participants	24 Participants	10 Participants	34 Participants

SECONDARY outcome

Timeframe: From the start of treatment and the earliest of disease progression, death, or the end of treatment. The data cut-off date is 29-Nov-2013.

Population: TS

Objective response was a best overall response of complete or partial response, recorded between the start of treatment and the earliest of disease progression, death, or the end of treatment. Some patients excluded from TS as they were not evaluable for determination of maximum tolerated dose. Thus the number of evaluable TS patients are not the same as the number of original TS patients.

Outcome measures

Outcome measures
Measure	Schedule A BI 847325 6 mg (A1) n=3 Participants Schedule A BI 847325 6 mg/day group. Schedule A: 2 weeks on treatment, 1 week off treatment, repeated every 3 weeks. BI 847325 tablet(s) administered once daily in the morning 1 hour before breakfast and taken with at least 250 mL of water.	Schedule A BI 847325 9 mg (A2) n=3 Participants Schedule A BI 847325 9 mg/day group. Schedule A: 2 weeks on treatment, 1 week off treatment, repeated every 3 weeks. BI 847325 tablet(s) administered once daily in the morning 1 hour before breakfast and taken with at least 250 mL of water.	Schedule A BI 847325 13 mg (A3) n=3 Participants Schedule A BI 847325 13 mg/day group. Schedule A: 2 weeks on treatment, 1 week off treatment, repeated every 3 weeks. BI 847325 tablet(s) administered once daily in the morning 1 hour before breakfast and taken with at least 250 mL of water.	Schedule A BI 847325 19 mg (A4) n=3 Participants Schedule A BI 847325 19 mg/day group. Schedule A: 2 weeks on treatment, 1 week off treatment, repeated every 3 weeks. BI 847325 tablet(s) administered once daily in the morning 1 hour before breakfast and taken with at least 250 mL of water.	Schedule A BI 847325 26 mg (A5) n=7 Participants Schedule A BI 847325 26 mg/day group. Schedule A: 2 weeks on treatment, 1 week off treatment, repeated every 3 weeks. BI 847325 tablet(s) administered once daily in the morning 1 hour before breakfast and taken with at least 250 mL of water.	Schedule A BI 847325 33 mg (A6) n=7 Participants Schedule A BI 847325 33 mg/day group. Schedule A: 2 weeks on treatment, 1 week off treatment, repeated every 3 weeks. BI 847325 tablet(s) administered once daily in the morning 1 hour before breakfast and taken with at least 250 mL of water.	Schedule A BI 847325 46 mg (A7) n=3 Participants Schedule A BI 847325 46 mg/day group. Schedule A: 2 weeks on treatment, 1 week off treatment, repeated every 3 weeks. BI 847325 tablet(s) administered once daily in the morning 1 hour before breakfast and taken with at least 250 mL of water.	Schedule A BI 847325 63 mg (A8) n=3 Participants Schedule A BI 847325 63 mg/day group. Schedule A: 2 weeks on treatment, 1 week off treatment, repeated every 3 weeks. BI 847325 tablet(s) administered once daily in the morning 1 hour before breakfast and taken with at least 250 mL of water.	Schedule A BI 847325 86 mg (A9) n=5 Participants Schedule A BI 847325 86 mg/day group. Schedule A: 2 weeks on treatment, 1 week off treatment, repeated every 3 weeks. BI 847325 tablet(s) administered once daily in the morning 1 hour before breakfast and taken with at least 250 mL of water.	Schedule A BI 847325 120 mg (A10) n=6 Participants Schedule A BI 847325 120 mg/day group. Schedule A: 2 weeks on treatment, 1 week off treatment, repeated every 3 weeks. BI 847325 tablet(s) administered once daily in the morning 1 hour before breakfast and taken with at least 250 mL of water.	Schedule A BI 847325 160 mg (A11) n=4 Participants Schedule A BI 847325 160 mg/day group. Schedule A: 2 weeks on treatment, 1 week off treatment, repeated every 3 weeks. BI 847325 tablet(s) administered once daily in the morning 1 hour before breakfast and taken with at least 250 mL of water.	Schedule B BI 847325 6 mg (B1) n=1 Participants Schedule B BI 847325 6 mg/day group. Schedule B: 5 days on treatment, 2 days off treatment, repeated every week, in 3-week cycles. BI 847325 tablet(s) administered once daily in the morning 1 hour before breakfast and taken with at least 250 mL of water.	Schedule B BI 847325 12 mg (B2) n=1 Participants Schedule B BI 847325 12 mg/day group. Schedule B: 5 days on treatment, 2 days off treatment, repeated every week, in 3-week cycles. BI 847325 tablet(s) administered once daily in the morning 1 hour before breakfast and taken with at least 250 mL of water.	Schedule B BI 847325 23 mg (B3) n=1 Participants Schedule B BI 847325 23 mg/day group. Schedule B: 5 days on treatment, 2 days off treatment, repeated every week, in 3-week cycles. BI 847325 tablet(s) administered once daily in the morning 1 hour before breakfast and taken with at least 250 mL of water.	Schedule B BI 847325 46 mg (B4) n=1 Participants Schedule B BI 847325 46 mg/day group. Schedule B: 5 days on treatment, 2 days off treatment, repeated every week, in 3-week cycles. BI 847325 tablet(s) administered once daily in the morning 1 hour before breakfast and taken with at least 250 mL of water.	Schedule B BI 847325 90 mg (B5) n=1 Participants Schedule B BI 847325 90 mg/day group. Schedule B: 5 days on treatment, 2 days off treatment, repeated every week, in 3-week cycles. BI 847325 tablet(s) administered once daily in the morning 1 hour before breakfast and taken with at least 250 mL of water.	Schedule B BI 847325 180 mg (B6) n=3 Participants Schedule B BI 847325 180 mg/day group. Schedule B: 5 days on treatment, 2 days off treatment, repeated every week, in 3-week cycles. BI 847325 tablet(s) administered once daily in the morning 1 hour before breakfast and taken with at least 250 mL of water.	Schedule B BI 847325 130 mg (B7) n=6 Participants Schedule B BI 847325 130 mg/day group. Schedule B: 5 days on treatment, 2 days off treatment, repeated every week, in 3-week cycles. BI 847325 tablet(s) administered once daily in the morning 1 hour before breakfast and taken with at least 250 mL of water.	Schedule B BI 847325 150 mg (B8) n=6 Participants Schedule B BI 847325 150 mg/day group. Schedule B: 5 days on treatment, 2 days off treatment, repeated every week, in 3-week cycles. BI 847325 tablet(s) administered once daily in the morning 1 hour before breakfast and taken with at least 250 mL of water.	Schedule A Total (Total A) n=47 Participants All patients with schedule A. Schedule A: 2 weeks on treatment, 1 week off treatment, repeated every 3 weeks.	Schedule B Total (Total B) n=22 Participants Schedule B total treated patients. Schedule B: 5 days on treatment, 2 days off treatment, repeated every week, in 3-week cycles.	Total Patients n=69 Participants Schedule A and B total patients.
Objective Response Objective response: Yes	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	1 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	1 Participants	0 Participants	1 Participants
Objective Response Objective response: No	3 Participants	3 Participants	3 Participants	3 Participants	7 Participants	7 Participants	3 Participants	3 Participants	5 Participants	6 Participants	3 Participants	1 Participants	1 Participants	1 Participants	1 Participants	3 Participants	3 Participants	6 Participants	6 Participants	46 Participants	22 Participants	68 Participants

SECONDARY outcome

Timeframe: From the start of treatment to the earliest of disease progression, death, or the end of treatment. The data cut-off date is 29-Nov-2013.

Population: TS

Disease control was a best overall response of complete response, partial response or stable disease, recorded between the start of treatment and the earliest of disease progression, death, or the end of treatment. Some patients excluded from TS as they were not evaluable for determination of maximum tolerated dose. Thus the number of evaluable TS patients are not the same as the number of original TS patients.

Outcome measures

Outcome measures
Measure	Schedule A BI 847325 6 mg (A1) n=3 Participants Schedule A BI 847325 6 mg/day group. Schedule A: 2 weeks on treatment, 1 week off treatment, repeated every 3 weeks. BI 847325 tablet(s) administered once daily in the morning 1 hour before breakfast and taken with at least 250 mL of water.	Schedule A BI 847325 9 mg (A2) n=3 Participants Schedule A BI 847325 9 mg/day group. Schedule A: 2 weeks on treatment, 1 week off treatment, repeated every 3 weeks. BI 847325 tablet(s) administered once daily in the morning 1 hour before breakfast and taken with at least 250 mL of water.	Schedule A BI 847325 13 mg (A3) n=3 Participants Schedule A BI 847325 13 mg/day group. Schedule A: 2 weeks on treatment, 1 week off treatment, repeated every 3 weeks. BI 847325 tablet(s) administered once daily in the morning 1 hour before breakfast and taken with at least 250 mL of water.	Schedule A BI 847325 19 mg (A4) n=3 Participants Schedule A BI 847325 19 mg/day group. Schedule A: 2 weeks on treatment, 1 week off treatment, repeated every 3 weeks. BI 847325 tablet(s) administered once daily in the morning 1 hour before breakfast and taken with at least 250 mL of water.	Schedule A BI 847325 26 mg (A5) n=7 Participants Schedule A BI 847325 26 mg/day group. Schedule A: 2 weeks on treatment, 1 week off treatment, repeated every 3 weeks. BI 847325 tablet(s) administered once daily in the morning 1 hour before breakfast and taken with at least 250 mL of water.	Schedule A BI 847325 33 mg (A6) n=7 Participants Schedule A BI 847325 33 mg/day group. Schedule A: 2 weeks on treatment, 1 week off treatment, repeated every 3 weeks. BI 847325 tablet(s) administered once daily in the morning 1 hour before breakfast and taken with at least 250 mL of water.	Schedule A BI 847325 46 mg (A7) n=3 Participants Schedule A BI 847325 46 mg/day group. Schedule A: 2 weeks on treatment, 1 week off treatment, repeated every 3 weeks. BI 847325 tablet(s) administered once daily in the morning 1 hour before breakfast and taken with at least 250 mL of water.	Schedule A BI 847325 63 mg (A8) n=3 Participants Schedule A BI 847325 63 mg/day group. Schedule A: 2 weeks on treatment, 1 week off treatment, repeated every 3 weeks. BI 847325 tablet(s) administered once daily in the morning 1 hour before breakfast and taken with at least 250 mL of water.	Schedule A BI 847325 86 mg (A9) n=5 Participants Schedule A BI 847325 86 mg/day group. Schedule A: 2 weeks on treatment, 1 week off treatment, repeated every 3 weeks. BI 847325 tablet(s) administered once daily in the morning 1 hour before breakfast and taken with at least 250 mL of water.	Schedule A BI 847325 120 mg (A10) n=6 Participants Schedule A BI 847325 120 mg/day group. Schedule A: 2 weeks on treatment, 1 week off treatment, repeated every 3 weeks. BI 847325 tablet(s) administered once daily in the morning 1 hour before breakfast and taken with at least 250 mL of water.	Schedule A BI 847325 160 mg (A11) n=4 Participants Schedule A BI 847325 160 mg/day group. Schedule A: 2 weeks on treatment, 1 week off treatment, repeated every 3 weeks. BI 847325 tablet(s) administered once daily in the morning 1 hour before breakfast and taken with at least 250 mL of water.	Schedule B BI 847325 6 mg (B1) n=1 Participants Schedule B BI 847325 6 mg/day group. Schedule B: 5 days on treatment, 2 days off treatment, repeated every week, in 3-week cycles. BI 847325 tablet(s) administered once daily in the morning 1 hour before breakfast and taken with at least 250 mL of water.	Schedule B BI 847325 12 mg (B2) n=1 Participants Schedule B BI 847325 12 mg/day group. Schedule B: 5 days on treatment, 2 days off treatment, repeated every week, in 3-week cycles. BI 847325 tablet(s) administered once daily in the morning 1 hour before breakfast and taken with at least 250 mL of water.	Schedule B BI 847325 23 mg (B3) n=1 Participants Schedule B BI 847325 23 mg/day group. Schedule B: 5 days on treatment, 2 days off treatment, repeated every week, in 3-week cycles. BI 847325 tablet(s) administered once daily in the morning 1 hour before breakfast and taken with at least 250 mL of water.	Schedule B BI 847325 46 mg (B4) n=1 Participants Schedule B BI 847325 46 mg/day group. Schedule B: 5 days on treatment, 2 days off treatment, repeated every week, in 3-week cycles. BI 847325 tablet(s) administered once daily in the morning 1 hour before breakfast and taken with at least 250 mL of water.	Schedule B BI 847325 90 mg (B5) n=1 Participants Schedule B BI 847325 90 mg/day group. Schedule B: 5 days on treatment, 2 days off treatment, repeated every week, in 3-week cycles. BI 847325 tablet(s) administered once daily in the morning 1 hour before breakfast and taken with at least 250 mL of water.	Schedule B BI 847325 180 mg (B6) n=3 Participants Schedule B BI 847325 180 mg/day group. Schedule B: 5 days on treatment, 2 days off treatment, repeated every week, in 3-week cycles. BI 847325 tablet(s) administered once daily in the morning 1 hour before breakfast and taken with at least 250 mL of water.	Schedule B BI 847325 130 mg (B7) n=6 Participants Schedule B BI 847325 130 mg/day group. Schedule B: 5 days on treatment, 2 days off treatment, repeated every week, in 3-week cycles. BI 847325 tablet(s) administered once daily in the morning 1 hour before breakfast and taken with at least 250 mL of water.	Schedule B BI 847325 150 mg (B8) n=6 Participants Schedule B BI 847325 150 mg/day group. Schedule B: 5 days on treatment, 2 days off treatment, repeated every week, in 3-week cycles. BI 847325 tablet(s) administered once daily in the morning 1 hour before breakfast and taken with at least 250 mL of water.	Schedule A Total (Total A) n=47 Participants All patients with schedule A. Schedule A: 2 weeks on treatment, 1 week off treatment, repeated every 3 weeks.	Schedule B Total (Total B) n=22 Participants Schedule B total treated patients. Schedule B: 5 days on treatment, 2 days off treatment, repeated every week, in 3-week cycles.	Total Patients n=69 Participants Schedule A and B total patients.
Disease Control Disease control: No	3 Participants	3 Participants	2 Participants	2 Participants	4 Participants	6 Participants	3 Participants	2 Participants	4 Participants	4 Participants	2 Participants	1 Participants	1 Participants	1 Participants	1 Participants	1 Participants	1 Participants	2 Participants	4 Participants	35 Participants	12 Participants	47 Participants
Disease Control Disease control: Yes	0 Participants	0 Participants	1 Participants	1 Participants	3 Participants	1 Participants	0 Participants	1 Participants	1 Participants	2 Participants	2 Participants	0 Participants	0 Participants	0 Participants	0 Participants	2 Participants	2 Participants	4 Participants	2 Participants	12 Participants	10 Participants	22 Participants

Deaths: 0 deaths

Total Patients

Serious events: 31 serious events

Other events: 68 other events

Deaths: 0 deaths

Serious adverse events

Serious adverse events
Measure	Schedule A BI 847325 6 mg (A1) n=3 participants at risk Schedule A BI 847325 6 mg/day group. Schedule A: 2 weeks on treatment, 1 week off treatment, repeated every 3 weeks. BI 847325 tablet(s) administered once daily in the morning 1 hour before breakfast and taken with at least 250 mL of water.	Schedule A BI 847325 9 mg (A2) n=3 participants at risk Schedule A BI 847325 9 mg/day group. Schedule A: 2 weeks on treatment, 1 week off treatment, repeated every 3 weeks. BI 847325 tablet(s) administered once daily in the morning 1 hour before breakfast and taken with at least 250 mL of water.	Schedule A BI 847325 13 mg (A3) n=3 participants at risk Schedule A BI 847325 13 mg/day group. Schedule A: 2 weeks on treatment, 1 week off treatment, repeated every 3 weeks. BI 847325 tablet(s) administered once daily in the morning 1 hour before breakfast and taken with at least 250 mL of water.	Schedule A BI 847325 19 mg (A4) n=3 participants at risk Schedule A BI 847325 19 mg/day group. Schedule A: 2 weeks on treatment, 1 week off treatment, repeated every 3 weeks. BI 847325 tablet(s) administered once daily in the morning 1 hour before breakfast and taken with at least 250 mL of water.	Schedule A BI 847325 26 mg (A5) n=7 participants at risk Schedule A BI 847325 26 mg/day group. Schedule A: 2 weeks on treatment, 1 week off treatment, repeated every 3 weeks. BI 847325 tablet(s) administered once daily in the morning 1 hour before breakfast and taken with at least 250 mL of water.	Schedule A BI 847325 33 mg (A6) n=7 participants at risk Schedule A BI 847325 33 mg/day group. Schedule A: 2 weeks on treatment, 1 week off treatment, repeated every 3 weeks. BI 847325 tablet(s) administered once daily in the morning 1 hour before breakfast and taken with at least 250 mL of water.	Schedule A BI 847325 46 mg (A7) n=3 participants at risk Schedule A BI 847325 46 mg/day group. Schedule A: 2 weeks on treatment, 1 week off treatment, repeated every 3 weeks. BI 847325 tablet(s) administered once daily in the morning 1 hour before breakfast and taken with at least 250 mL of water.	Schedule A BI 847325 63 mg (A8) n=3 participants at risk Schedule A BI 847325 63 mg/day group. Schedule A: 2 weeks on treatment, 1 week off treatment, repeated every 3 weeks. BI 847325 tablet(s) administered once daily in the morning 1 hour before breakfast and taken with at least 250 mL of water.	Schedule A BI 847325 86 mg (A9) n=5 participants at risk Schedule A BI 847325 86 mg/day group. Schedule A: 2 weeks on treatment, 1 week off treatment, repeated every 3 weeks. BI 847325 tablet(s) administered once daily in the morning 1 hour before breakfast and taken with at least 250 mL of water.	Schedule A BI 847325 120 mg (A10) n=6 participants at risk Schedule A BI 847325 120 mg/day group. Schedule A: 2 weeks on treatment, 1 week off treatment, repeated every 3 weeks. BI 847325 tablet(s) administered once daily in the morning 1 hour before breakfast and taken with at least 250 mL of water.	Schedule A BI 847325 160 mg (A11) n=4 participants at risk Schedule A BI 847325 160 mg/day group. Schedule A: 2 weeks on treatment, 1 week off treatment, repeated every 3 weeks. BI 847325 tablet(s) administered once daily in the morning 1 hour before breakfast and taken with at least 250 mL of water.	Schedule A Total (Total A) n=47 participants at risk All patients with schedule A. Schedule A: 2 weeks on treatment, 1 week off treatment, repeated every 3 weeks.	Schedule B BI 847325 6 mg (B1) n=1 participants at risk Schedule B BI 847325 6 mg/day group. Schedule B: 5 days on treatment, 2 days off treatment, repeated every week, in 3-week cycles. BI 847325 tablet(s) administered once daily in the morning 1 hour before breakfast and taken with at least 250 mL of water.	Schedule B BI 847325 12 mg (B2) n=1 participants at risk Schedule B BI 847325 12 mg/day group. Schedule B: 5 days on treatment, 2 days off treatment, repeated every week, in 3-week cycles. BI 847325 tablet(s) administered once daily in the morning 1 hour before breakfast and taken with at least 250 mL of water.	Schedule B BI 847325 23 mg (B3) n=1 participants at risk Schedule B BI 847325 23 mg/day group. Schedule B: 5 days on treatment, 2 days off treatment, repeated every week, in 3-week cycles. BI 847325 tablet(s) administered once daily in the morning 1 hour before breakfast and taken with at least 250 mL of water.	Schedule B BI 847325 46 mg (B4) n=1 participants at risk Schedule B BI 847325 46 mg/day group. Schedule B: 5 days on treatment, 2 days off treatment, repeated every week, in 3-week cycles. BI 847325 tablet(s) administered once daily in the morning 1 hour before breakfast and taken with at least 250 mL of water.	Schedule B BI 847325 90 mg (B5) n=3 participants at risk Schedule B BI 847325 90 mg/day group. Schedule B: 5 days on treatment, 2 days off treatment, repeated every week, in 3-week cycles. BI 847325 tablet(s) administered once daily in the morning 1 hour before breakfast and taken with at least 250 mL of water.	Schedule B BI 847325 180 mg (B6) n=3 participants at risk Schedule B BI 847325 180 mg/day group. Schedule B: 5 days on treatment, 2 days off treatment, repeated every week, in 3-week cycles. BI 847325 tablet(s) administered once daily in the morning 1 hour before breakfast and taken with at least 250 mL of water.	Schedule B BI 847325 130 mg (B7) n=6 participants at risk Schedule B BI 847325 130 mg/day group. Schedule B: 5 days on treatment, 2 days off treatment, repeated every week, in 3-week cycles. BI 847325 tablet(s) administered once daily in the morning 1 hour before breakfast and taken with at least 250 mL of water.	Schedule B BI 847325 150 mg (B8) n=6 participants at risk Schedule B BI 847325 150 mg/day group. Schedule B: 5 days on treatment, 2 days off treatment, repeated every week, in 3-week cycles. BI 847325 tablet(s) administered once daily in the morning 1 hour before breakfast and taken with at least 250 mL of water.	Schedule B Total (Total B) n=22 participants at risk Schedule B total treated patients. Schedule B: 5 days on treatment, 2 days off treatment, repeated every week, in 3-week cycles.	Total Patients n=69 participants at risk Schedule A and B total patients.
Reproductive system and breast disorders Pelvic pain	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	14.3% 1/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/5 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/4 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	2.1% 1/47 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/22 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	1.4% 1/69 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days
Blood and lymphatic system disorders Febrile neutropenia	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/5 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	50.0% 2/4 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	4.3% 2/47 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	33.3% 1/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	16.7% 1/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	16.7% 1/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	13.6% 3/22 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	7.2% 5/69 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days
Cardiac disorders Cardiac tamponade	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	20.0% 1/5 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/4 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	2.1% 1/47 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/22 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	1.4% 1/69 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days
Cardiac disorders Myocardial infarction	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/5 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	25.0% 1/4 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	2.1% 1/47 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/22 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	1.4% 1/69 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days
Gastrointestinal disorders Ileus	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/5 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	25.0% 1/4 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	2.1% 1/47 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/22 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	1.4% 1/69 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days
Gastrointestinal disorders Intestinal obstruction	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	14.3% 1/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/5 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/4 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	2.1% 1/47 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/22 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	1.4% 1/69 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days
Gastrointestinal disorders Nausea	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/5 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/4 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/47 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	16.7% 1/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	4.5% 1/22 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	1.4% 1/69 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days
Gastrointestinal disorders Oesophageal varices haemorrhage	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	33.3% 1/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/5 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/4 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	2.1% 1/47 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/22 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	1.4% 1/69 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days
General disorders Euthanasia	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/5 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/4 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/47 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	100.0% 1/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	4.5% 1/22 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	1.4% 1/69 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days
General disorders Fatigue	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	14.3% 1/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/5 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/4 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	2.1% 1/47 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/22 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	1.4% 1/69 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days
General disorders General physical health deterioration	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	60.0% 3/5 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/4 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	6.4% 3/47 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	33.3% 1/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	16.7% 1/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	9.1% 2/22 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	7.2% 5/69 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days
General disorders Pain	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	14.3% 1/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	14.3% 1/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/5 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	16.7% 1/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/4 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	6.4% 3/47 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/22 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	4.3% 3/69 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days
Hepatobiliary disorders Cholangitis	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/5 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	16.7% 1/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/4 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	2.1% 1/47 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/22 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	1.4% 1/69 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days
Hepatobiliary disorders Cholecystitis acute	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/5 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	25.0% 1/4 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	2.1% 1/47 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/22 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	1.4% 1/69 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days
Hepatobiliary disorders Portal vein thrombosis	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	20.0% 1/5 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/4 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	2.1% 1/47 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/22 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	1.4% 1/69 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days
Immune system disorders Drug hypersensitivity	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/5 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/4 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/47 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	16.7% 1/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	4.5% 1/22 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	1.4% 1/69 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days
Infections and infestations Cellulitis	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/5 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/4 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/47 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	33.3% 1/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	4.5% 1/22 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	1.4% 1/69 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days
Infections and infestations Pneumonia	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	14.3% 1/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/5 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	25.0% 1/4 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	4.3% 2/47 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/22 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	2.9% 2/69 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days
Infections and infestations Sepsis	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/5 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/4 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/47 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	33.3% 1/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	4.5% 1/22 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	1.4% 1/69 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days
Injury, poisoning and procedural complications Fall	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	20.0% 1/5 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/4 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	2.1% 1/47 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/22 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	1.4% 1/69 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days
Investigations Aspartate aminotransferase increased	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/5 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/4 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/47 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	16.7% 1/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	4.5% 1/22 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	1.4% 1/69 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days
Investigations Blood bilirubin increased	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	33.3% 1/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/5 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/4 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	2.1% 1/47 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	16.7% 1/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	4.5% 1/22 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	2.9% 2/69 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days
Investigations Ejection fraction decreased	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	14.3% 1/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/5 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/4 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	2.1% 1/47 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/22 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	1.4% 1/69 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days
Investigations Electrocardiogram ST segment elevation	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	14.3% 1/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/5 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/4 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	2.1% 1/47 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/22 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	1.4% 1/69 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days
Investigations Troponin I increased	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	14.3% 1/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/5 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/4 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	2.1% 1/47 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/22 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	1.4% 1/69 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days
Metabolism and nutrition disorders Dehydration	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	14.3% 1/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/5 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/4 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	2.1% 1/47 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/22 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	1.4% 1/69 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days
Metabolism and nutrition disorders Hypercalcaemia	33.3% 1/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	14.3% 1/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	33.3% 1/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/5 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/4 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	6.4% 3/47 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	100.0% 1/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	4.5% 1/22 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	5.8% 4/69 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days
Metabolism and nutrition disorders Hypokalaemia	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/5 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	25.0% 1/4 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	2.1% 1/47 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/22 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	1.4% 1/69 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days
Musculoskeletal and connective tissue disorders Back pain	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	14.3% 1/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/5 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/4 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	2.1% 1/47 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/22 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	1.4% 1/69 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days
Musculoskeletal and connective tissue disorders Musculoskeletal chest pain	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	14.3% 1/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/5 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/4 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	2.1% 1/47 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/22 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	1.4% 1/69 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Malignant neoplasm progression	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	28.6% 2/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/5 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/4 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	4.3% 2/47 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/22 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	2.9% 2/69 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days
Respiratory, thoracic and mediastinal disorders Chronic obstructive pulmonary disease	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/5 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	25.0% 1/4 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	2.1% 1/47 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/22 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	1.4% 1/69 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days
Respiratory, thoracic and mediastinal disorders Dyspnoea	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	14.3% 1/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/5 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/4 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	2.1% 1/47 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	100.0% 1/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	16.7% 1/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	9.1% 2/22 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	4.3% 3/69 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days
Respiratory, thoracic and mediastinal disorders Pleural effusion	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/5 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/4 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/47 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	16.7% 1/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	4.5% 1/22 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	1.4% 1/69 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days
Respiratory, thoracic and mediastinal disorders Respiratory failure	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	14.3% 1/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/5 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/4 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	2.1% 1/47 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/22 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	1.4% 1/69 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days

Other adverse events

Other adverse events
Measure	Schedule A BI 847325 6 mg (A1) n=3 participants at risk Schedule A BI 847325 6 mg/day group. Schedule A: 2 weeks on treatment, 1 week off treatment, repeated every 3 weeks. BI 847325 tablet(s) administered once daily in the morning 1 hour before breakfast and taken with at least 250 mL of water.	Schedule A BI 847325 9 mg (A2) n=3 participants at risk Schedule A BI 847325 9 mg/day group. Schedule A: 2 weeks on treatment, 1 week off treatment, repeated every 3 weeks. BI 847325 tablet(s) administered once daily in the morning 1 hour before breakfast and taken with at least 250 mL of water.	Schedule A BI 847325 13 mg (A3) n=3 participants at risk Schedule A BI 847325 13 mg/day group. Schedule A: 2 weeks on treatment, 1 week off treatment, repeated every 3 weeks. BI 847325 tablet(s) administered once daily in the morning 1 hour before breakfast and taken with at least 250 mL of water.	Schedule A BI 847325 19 mg (A4) n=3 participants at risk Schedule A BI 847325 19 mg/day group. Schedule A: 2 weeks on treatment, 1 week off treatment, repeated every 3 weeks. BI 847325 tablet(s) administered once daily in the morning 1 hour before breakfast and taken with at least 250 mL of water.	Schedule A BI 847325 26 mg (A5) n=7 participants at risk Schedule A BI 847325 26 mg/day group. Schedule A: 2 weeks on treatment, 1 week off treatment, repeated every 3 weeks. BI 847325 tablet(s) administered once daily in the morning 1 hour before breakfast and taken with at least 250 mL of water.	Schedule A BI 847325 33 mg (A6) n=7 participants at risk Schedule A BI 847325 33 mg/day group. Schedule A: 2 weeks on treatment, 1 week off treatment, repeated every 3 weeks. BI 847325 tablet(s) administered once daily in the morning 1 hour before breakfast and taken with at least 250 mL of water.	Schedule A BI 847325 46 mg (A7) n=3 participants at risk Schedule A BI 847325 46 mg/day group. Schedule A: 2 weeks on treatment, 1 week off treatment, repeated every 3 weeks. BI 847325 tablet(s) administered once daily in the morning 1 hour before breakfast and taken with at least 250 mL of water.	Schedule A BI 847325 63 mg (A8) n=3 participants at risk Schedule A BI 847325 63 mg/day group. Schedule A: 2 weeks on treatment, 1 week off treatment, repeated every 3 weeks. BI 847325 tablet(s) administered once daily in the morning 1 hour before breakfast and taken with at least 250 mL of water.	Schedule A BI 847325 86 mg (A9) n=5 participants at risk Schedule A BI 847325 86 mg/day group. Schedule A: 2 weeks on treatment, 1 week off treatment, repeated every 3 weeks. BI 847325 tablet(s) administered once daily in the morning 1 hour before breakfast and taken with at least 250 mL of water.	Schedule A BI 847325 120 mg (A10) n=6 participants at risk Schedule A BI 847325 120 mg/day group. Schedule A: 2 weeks on treatment, 1 week off treatment, repeated every 3 weeks. BI 847325 tablet(s) administered once daily in the morning 1 hour before breakfast and taken with at least 250 mL of water.	Schedule A BI 847325 160 mg (A11) n=4 participants at risk Schedule A BI 847325 160 mg/day group. Schedule A: 2 weeks on treatment, 1 week off treatment, repeated every 3 weeks. BI 847325 tablet(s) administered once daily in the morning 1 hour before breakfast and taken with at least 250 mL of water.	Schedule A Total (Total A) n=47 participants at risk All patients with schedule A. Schedule A: 2 weeks on treatment, 1 week off treatment, repeated every 3 weeks.	Schedule B BI 847325 6 mg (B1) n=1 participants at risk Schedule B BI 847325 6 mg/day group. Schedule B: 5 days on treatment, 2 days off treatment, repeated every week, in 3-week cycles. BI 847325 tablet(s) administered once daily in the morning 1 hour before breakfast and taken with at least 250 mL of water.	Schedule B BI 847325 12 mg (B2) n=1 participants at risk Schedule B BI 847325 12 mg/day group. Schedule B: 5 days on treatment, 2 days off treatment, repeated every week, in 3-week cycles. BI 847325 tablet(s) administered once daily in the morning 1 hour before breakfast and taken with at least 250 mL of water.	Schedule B BI 847325 23 mg (B3) n=1 participants at risk Schedule B BI 847325 23 mg/day group. Schedule B: 5 days on treatment, 2 days off treatment, repeated every week, in 3-week cycles. BI 847325 tablet(s) administered once daily in the morning 1 hour before breakfast and taken with at least 250 mL of water.	Schedule B BI 847325 46 mg (B4) n=1 participants at risk Schedule B BI 847325 46 mg/day group. Schedule B: 5 days on treatment, 2 days off treatment, repeated every week, in 3-week cycles. BI 847325 tablet(s) administered once daily in the morning 1 hour before breakfast and taken with at least 250 mL of water.	Schedule B BI 847325 90 mg (B5) n=3 participants at risk Schedule B BI 847325 90 mg/day group. Schedule B: 5 days on treatment, 2 days off treatment, repeated every week, in 3-week cycles. BI 847325 tablet(s) administered once daily in the morning 1 hour before breakfast and taken with at least 250 mL of water.	Schedule B BI 847325 180 mg (B6) n=3 participants at risk Schedule B BI 847325 180 mg/day group. Schedule B: 5 days on treatment, 2 days off treatment, repeated every week, in 3-week cycles. BI 847325 tablet(s) administered once daily in the morning 1 hour before breakfast and taken with at least 250 mL of water.	Schedule B BI 847325 130 mg (B7) n=6 participants at risk Schedule B BI 847325 130 mg/day group. Schedule B: 5 days on treatment, 2 days off treatment, repeated every week, in 3-week cycles. BI 847325 tablet(s) administered once daily in the morning 1 hour before breakfast and taken with at least 250 mL of water.	Schedule B BI 847325 150 mg (B8) n=6 participants at risk Schedule B BI 847325 150 mg/day group. Schedule B: 5 days on treatment, 2 days off treatment, repeated every week, in 3-week cycles. BI 847325 tablet(s) administered once daily in the morning 1 hour before breakfast and taken with at least 250 mL of water.	Schedule B Total (Total B) n=22 participants at risk Schedule B total treated patients. Schedule B: 5 days on treatment, 2 days off treatment, repeated every week, in 3-week cycles.	Total Patients n=69 participants at risk Schedule A and B total patients.
Eye disorders Ocular discomfort	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	14.3% 1/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/5 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/4 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	2.1% 1/47 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/22 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	1.4% 1/69 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days
Gastrointestinal disorders Abdominal pain	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	40.0% 2/5 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/4 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	4.3% 2/47 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	100.0% 1/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	33.3% 1/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	33.3% 1/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	33.3% 2/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	22.7% 5/22 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	10.1% 7/69 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days
Infections and infestations Urinary tract infection	33.3% 1/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	14.3% 1/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	33.3% 1/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/5 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	16.7% 1/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	25.0% 1/4 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	10.6% 5/47 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	16.7% 1/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	4.5% 1/22 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	8.7% 6/69 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days
Eye disorders Vision blurred	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	33.3% 1/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/5 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/4 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	2.1% 1/47 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/22 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	1.4% 1/69 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days
Blood and lymphatic system disorders Anaemia	33.3% 1/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	33.3% 1/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	33.3% 1/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	28.6% 2/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	42.9% 3/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	66.7% 2/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	66.7% 2/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	20.0% 1/5 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	50.0% 3/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	75.0% 3/4 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	40.4% 19/47 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	100.0% 1/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	66.7% 2/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	16.7% 1/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	83.3% 5/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	40.9% 9/22 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	40.6% 28/69 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days
Blood and lymphatic system disorders Coagulopathy	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/5 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	16.7% 1/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/4 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	2.1% 1/47 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/22 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	1.4% 1/69 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days
Blood and lymphatic system disorders Leukopenia	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/5 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	25.0% 1/4 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	2.1% 1/47 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	66.7% 2/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	9.1% 2/22 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	4.3% 3/69 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days
Blood and lymphatic system disorders Lymphopenia	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	14.3% 1/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/5 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	16.7% 1/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	25.0% 1/4 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	6.4% 3/47 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	33.3% 1/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	33.3% 1/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	9.1% 2/22 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	7.2% 5/69 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days
Blood and lymphatic system disorders Neutropenia	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	33.3% 1/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	14.3% 1/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/5 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	33.3% 2/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	50.0% 2/4 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	12.8% 6/47 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	33.3% 1/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	66.7% 2/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	16.7% 1/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	16.7% 1/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	22.7% 5/22 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	15.9% 11/69 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days
Blood and lymphatic system disorders Thrombocytopenia	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	28.6% 2/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	33.3% 1/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/5 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	16.7% 1/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/4 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	8.5% 4/47 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	66.7% 2/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	16.7% 1/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	13.6% 3/22 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	10.1% 7/69 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days
Cardiac disorders Atrioventricular block first degree	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/5 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	25.0% 1/4 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	2.1% 1/47 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/22 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	1.4% 1/69 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days
Cardiac disorders Sinus tachycardia	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/5 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/4 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/47 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	16.7% 1/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	4.5% 1/22 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	1.4% 1/69 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days
Cardiac disorders Supraventricular tachycardia	33.3% 1/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/5 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/4 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	2.1% 1/47 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/22 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	1.4% 1/69 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days
Ear and labyrinth disorders Vertigo	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	28.6% 2/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/5 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/4 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	4.3% 2/47 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/22 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	2.9% 2/69 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days
Endocrine disorders Adrenal mass	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	14.3% 1/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/5 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/4 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	2.1% 1/47 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/22 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	1.4% 1/69 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days
Endocrine disorders Endocrine disorder	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	33.3% 1/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/5 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/4 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	2.1% 1/47 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/22 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	1.4% 1/69 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days
Eye disorders Conjunctivitis	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	20.0% 1/5 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/4 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	2.1% 1/47 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/22 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	1.4% 1/69 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days
Eye disorders Diplopia	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	14.3% 1/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/5 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/4 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	2.1% 1/47 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/22 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	1.4% 1/69 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days
Gastrointestinal disorders Abdominal pain upper	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/5 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	16.7% 1/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/4 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	2.1% 1/47 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	33.3% 1/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	16.7% 1/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	9.1% 2/22 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	4.3% 3/69 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days
Gastrointestinal disorders Anal fissure	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/5 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/4 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/47 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	33.3% 1/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	4.5% 1/22 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	1.4% 1/69 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days
Gastrointestinal disorders Anorectal discomfort	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/5 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	16.7% 1/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/4 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	2.1% 1/47 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/22 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	1.4% 1/69 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days
Gastrointestinal disorders Ascites	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	33.3% 1/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/5 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/4 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	2.1% 1/47 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	33.3% 1/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	4.5% 1/22 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	2.9% 2/69 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days
Gastrointestinal disorders Colitis	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/5 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	25.0% 1/4 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	2.1% 1/47 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	16.7% 1/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	4.5% 1/22 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	2.9% 2/69 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days
Gastrointestinal disorders Constipation	33.3% 1/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	33.3% 1/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	33.3% 1/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	28.6% 2/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	28.6% 2/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	66.7% 2/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	20.0% 1/5 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	33.3% 2/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/4 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	25.5% 12/47 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	100.0% 1/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	33.3% 1/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	16.7% 1/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	13.6% 3/22 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	21.7% 15/69 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days
Gastrointestinal disorders Diarrhoea	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	33.3% 1/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	33.3% 1/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	42.9% 3/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	66.7% 2/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	33.3% 1/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	80.0% 4/5 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	33.3% 2/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	50.0% 2/4 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	34.0% 16/47 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	100.0% 3/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	66.7% 2/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	100.0% 6/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	66.7% 4/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	68.2% 15/22 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	44.9% 31/69 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days
Gastrointestinal disorders Dry mouth	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	20.0% 1/5 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/4 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	2.1% 1/47 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/22 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	1.4% 1/69 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days
Gastrointestinal disorders Dyspepsia	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	14.3% 1/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/5 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/4 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	2.1% 1/47 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	33.3% 2/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	9.1% 2/22 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	4.3% 3/69 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days
Gastrointestinal disorders Faecaloma	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/5 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/4 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/47 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	33.3% 1/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	4.5% 1/22 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	1.4% 1/69 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days
Gastrointestinal disorders Flatulence	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/5 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/4 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/47 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	16.7% 1/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	4.5% 1/22 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	1.4% 1/69 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days
Gastrointestinal disorders Haemorrhoids	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/5 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	16.7% 1/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	25.0% 1/4 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	4.3% 2/47 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/22 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	2.9% 2/69 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days
Gastrointestinal disorders Mouth ulceration	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	20.0% 1/5 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/4 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	2.1% 1/47 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	16.7% 1/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	4.5% 1/22 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	2.9% 2/69 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days
Gastrointestinal disorders Nausea	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	33.3% 1/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	42.9% 3/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	14.3% 1/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	33.3% 1/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	80.0% 4/5 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	50.0% 3/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	50.0% 2/4 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	31.9% 15/47 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	100.0% 1/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	33.3% 1/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	66.7% 4/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	16.7% 1/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	31.8% 7/22 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	31.9% 22/69 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days
Gastrointestinal disorders Oesophagitis	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/5 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/4 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/47 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	16.7% 1/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	4.5% 1/22 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	1.4% 1/69 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days
Gastrointestinal disorders Stomatitis	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/5 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	16.7% 1/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	25.0% 1/4 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	4.3% 2/47 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	33.3% 2/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	9.1% 2/22 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	5.8% 4/69 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days
Gastrointestinal disorders Tooth disorder	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	33.3% 1/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/5 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/4 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	2.1% 1/47 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/22 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	1.4% 1/69 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days
Gastrointestinal disorders Vomiting	66.7% 2/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	71.4% 5/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	40.0% 2/5 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	50.0% 3/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	50.0% 2/4 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	29.8% 14/47 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	33.3% 1/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	33.3% 1/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	83.3% 5/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	16.7% 1/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	36.4% 8/22 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	31.9% 22/69 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days
General disorders Asthenia	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	33.3% 1/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	20.0% 1/5 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	16.7% 1/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/4 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	6.4% 3/47 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	16.7% 1/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	4.5% 1/22 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	5.8% 4/69 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days
General disorders Chest pain	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	33.3% 1/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/5 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/4 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	2.1% 1/47 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/22 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	1.4% 1/69 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days
General disorders Fatigue	66.7% 2/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	100.0% 3/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	33.3% 1/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	66.7% 2/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	42.9% 3/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	57.1% 4/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	33.3% 1/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	66.7% 2/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	40.0% 2/5 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	66.7% 4/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	75.0% 3/4 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	57.4% 27/47 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	100.0% 1/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	33.3% 1/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	83.3% 5/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	50.0% 3/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	45.5% 10/22 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	53.6% 37/69 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days
General disorders General physical health deterioration	33.3% 1/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	14.3% 1/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	14.3% 1/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	33.3% 1/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	33.3% 1/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/5 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/4 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	10.6% 5/47 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/22 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	7.2% 5/69 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days
General disorders Oedema	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/5 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/4 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/47 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	16.7% 1/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	4.5% 1/22 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	1.4% 1/69 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days
General disorders Oedema peripheral	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	28.6% 2/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	66.7% 2/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/5 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/4 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	8.5% 4/47 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/22 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	5.8% 4/69 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days
General disorders Pain	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	66.7% 2/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	14.3% 1/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	28.6% 2/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/5 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	33.3% 2/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/4 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	14.9% 7/47 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	33.3% 1/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	16.7% 1/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	16.7% 1/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	13.6% 3/22 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	14.5% 10/69 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days
General disorders Pyrexia	33.3% 1/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	14.3% 1/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	33.3% 1/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	20.0% 1/5 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	16.7% 1/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	25.0% 1/4 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	12.8% 6/47 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/22 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	8.7% 6/69 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days
General disorders Thrombosis in device	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	33.3% 1/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/5 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/4 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	2.1% 1/47 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/22 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	1.4% 1/69 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days
Hepatobiliary disorders Hepatic pain	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	14.3% 1/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/5 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/4 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	2.1% 1/47 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/22 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	1.4% 1/69 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days
Hepatobiliary disorders Hyperbilirubinaemia	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	14.3% 1/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/5 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/4 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	2.1% 1/47 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/22 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	1.4% 1/69 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days
Immune system disorders Hypersensitivity	33.3% 1/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/5 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/4 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	2.1% 1/47 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/22 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	1.4% 1/69 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days
Infections and infestations Bronchitis	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	33.3% 1/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/5 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/4 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	2.1% 1/47 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/22 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	1.4% 1/69 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days
Infections and infestations Cystitis	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/5 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/4 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/47 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	16.7% 1/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	4.5% 1/22 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	1.4% 1/69 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days
Infections and infestations Febrile infection	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/5 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	16.7% 1/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/4 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	2.1% 1/47 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/22 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	1.4% 1/69 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days
Infections and infestations Folliculitis	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/5 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/4 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/47 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	33.3% 1/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	4.5% 1/22 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	1.4% 1/69 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days
Infections and infestations Herpes zoster	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/5 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/4 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/47 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	16.7% 1/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	4.5% 1/22 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	1.4% 1/69 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days
Infections and infestations Infection	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/5 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/4 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/47 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	33.3% 1/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	4.5% 1/22 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	1.4% 1/69 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days
Infections and infestations Nail infection	33.3% 1/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/5 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/4 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	2.1% 1/47 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/22 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	1.4% 1/69 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days
Infections and infestations Nasopharyngitis	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/5 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/4 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/47 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	33.3% 1/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	16.7% 1/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	9.1% 2/22 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	2.9% 2/69 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days
Infections and infestations Oral herpes	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	20.0% 1/5 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/4 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	2.1% 1/47 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/22 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	1.4% 1/69 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days
Infections and infestations Pharyngitis	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	14.3% 1/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/5 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/4 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	2.1% 1/47 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/22 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	1.4% 1/69 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days
Infections and infestations Pneumonia	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/5 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	25.0% 1/4 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	2.1% 1/47 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/22 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	1.4% 1/69 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days
Infections and infestations Rhinitis	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/5 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/4 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/47 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	33.3% 1/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	4.5% 1/22 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	1.4% 1/69 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days
Infections and infestations Sepsis	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/5 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/4 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/47 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	16.7% 1/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	4.5% 1/22 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	1.4% 1/69 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days
Infections and infestations Tooth abscess	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	33.3% 1/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/5 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/4 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	2.1% 1/47 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/22 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	1.4% 1/69 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days
Infections and infestations Upper respiratory tract infection	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/5 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	16.7% 1/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/4 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	2.1% 1/47 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/22 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	1.4% 1/69 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days
Infections and infestations Vulvovaginal candidiasis	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/5 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	25.0% 1/4 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	2.1% 1/47 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/22 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	1.4% 1/69 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days
Infections and infestations Wound infection	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	33.3% 1/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/5 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/4 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	2.1% 1/47 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/22 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	1.4% 1/69 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days
Injury, poisoning and procedural complications Fall	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/5 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/4 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/47 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	16.7% 1/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	4.5% 1/22 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	1.4% 1/69 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days
Injury, poisoning and procedural complications Humerus fracture	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/5 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/4 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/47 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	33.3% 1/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	4.5% 1/22 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	1.4% 1/69 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days
Injury, poisoning and procedural complications Pelvic fracture	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/5 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/4 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/47 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	33.3% 1/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	4.5% 1/22 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	1.4% 1/69 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days
Injury, poisoning and procedural complications Radiation alopecia	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	14.3% 1/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/5 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/4 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	2.1% 1/47 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/22 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	1.4% 1/69 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days
Injury, poisoning and procedural complications Rib fracture	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/5 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/4 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/47 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	33.3% 1/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	4.5% 1/22 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	1.4% 1/69 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days
Investigations Alanine aminotransferase increased	33.3% 1/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	33.3% 1/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	33.3% 1/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	20.0% 1/5 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	33.3% 2/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/4 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	12.8% 6/47 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	33.3% 2/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	9.1% 2/22 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	11.6% 8/69 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days
Investigations Amylase increased	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/5 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	25.0% 1/4 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	2.1% 1/47 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/22 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	1.4% 1/69 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days
Investigations Aspartate aminotransferase increased	33.3% 1/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	33.3% 1/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	33.3% 1/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	20.0% 1/5 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	16.7% 1/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/4 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	10.6% 5/47 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	16.7% 1/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	4.5% 1/22 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	8.7% 6/69 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days
Investigations Blood alkaline phosphatase increased	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	66.7% 2/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/5 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	16.7% 1/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/4 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	6.4% 3/47 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	33.3% 1/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	4.5% 1/22 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	5.8% 4/69 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days
Investigations Blood bilirubin increased	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	14.3% 1/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	20.0% 1/5 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/4 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	4.3% 2/47 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/22 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	2.9% 2/69 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days
Investigations Blood creatine phosphokinase increased	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	14.3% 1/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	14.3% 1/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/5 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/4 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	4.3% 2/47 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/22 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	2.9% 2/69 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days
Investigations Blood creatinine increased	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	33.3% 1/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/5 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	16.7% 1/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/4 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	4.3% 2/47 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/22 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	2.9% 2/69 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days
Investigations Blood lactate dehydrogenase increased	33.3% 1/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/5 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/4 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	2.1% 1/47 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/22 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	1.4% 1/69 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days
Investigations Electrocardiogram QT prolonged	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/5 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/4 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/47 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	33.3% 1/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	4.5% 1/22 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	1.4% 1/69 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days
Investigations Haematocrit decreased	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/5 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/4 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/47 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	33.3% 1/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	4.5% 1/22 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	1.4% 1/69 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days
Investigations Lipase increased	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/5 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	25.0% 1/4 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	2.1% 1/47 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/22 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	1.4% 1/69 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days
Investigations Lymphocyte count decreased	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/5 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/4 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/47 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	33.3% 1/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	4.5% 1/22 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	1.4% 1/69 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days
Investigations Troponin T increased	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	33.3% 1/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/5 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	16.7% 1/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	25.0% 1/4 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	6.4% 3/47 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/22 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	4.3% 3/69 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days
Investigations Troponin increased	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	14.3% 1/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/5 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/4 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	2.1% 1/47 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/22 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	1.4% 1/69 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days
Investigations Weight decreased	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	14.3% 1/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/5 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	16.7% 1/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/4 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	4.3% 2/47 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	100.0% 1/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	16.7% 1/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	9.1% 2/22 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	5.8% 4/69 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days
Metabolism and nutrition disorders Decreased appetite	33.3% 1/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	100.0% 3/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	33.3% 1/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	33.3% 1/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	28.6% 2/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	14.3% 1/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	33.3% 1/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	40.0% 2/5 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	33.3% 2/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	25.0% 1/4 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	31.9% 15/47 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	66.7% 4/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	16.7% 1/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	22.7% 5/22 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	29.0% 20/69 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days
Metabolism and nutrition disorders Dehydration	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/5 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	25.0% 1/4 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	2.1% 1/47 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/22 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	1.4% 1/69 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days
Metabolism and nutrition disorders Hypercalcaemia	33.3% 1/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/5 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/4 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	2.1% 1/47 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	100.0% 1/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	4.5% 1/22 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	2.9% 2/69 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days
Metabolism and nutrition disorders Hypoalbuminaemia	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/5 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	25.0% 1/4 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	2.1% 1/47 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	16.7% 1/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	4.5% 1/22 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	2.9% 2/69 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days
Metabolism and nutrition disorders Hypocalcaemia	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/5 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	16.7% 1/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	25.0% 1/4 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	4.3% 2/47 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/22 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	2.9% 2/69 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days
Metabolism and nutrition disorders Hypokalaemia	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	33.3% 1/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	14.3% 1/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	33.3% 1/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	20.0% 1/5 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	16.7% 1/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	25.0% 1/4 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	12.8% 6/47 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	33.3% 1/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	16.7% 1/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	16.7% 1/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	13.6% 3/22 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	13.0% 9/69 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days
Metabolism and nutrition disorders Hypomagnesaemia	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	33.3% 1/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/5 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	50.0% 2/4 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	6.4% 3/47 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/22 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	4.3% 3/69 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days
Metabolism and nutrition disorders Hyponatraemia	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	14.3% 1/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/5 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	25.0% 1/4 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	4.3% 2/47 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	33.3% 1/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	16.7% 1/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	9.1% 2/22 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	5.8% 4/69 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days
Metabolism and nutrition disorders Hypophosphataemia	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/5 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	16.7% 1/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	25.0% 1/4 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	4.3% 2/47 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	16.7% 1/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	4.5% 1/22 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	4.3% 3/69 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days
Metabolism and nutrition disorders Hypovitaminosis	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/5 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/4 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/47 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	16.7% 1/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	4.5% 1/22 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	1.4% 1/69 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days
Musculoskeletal and connective tissue disorders Arthralgia	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	33.3% 1/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/5 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/4 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	2.1% 1/47 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/22 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	1.4% 1/69 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days
Musculoskeletal and connective tissue disorders Back pain	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	33.3% 1/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	14.3% 1/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/5 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/4 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	4.3% 2/47 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	100.0% 1/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	16.7% 1/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	9.1% 2/22 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	5.8% 4/69 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days
Musculoskeletal and connective tissue disorders Muscle spasms	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/5 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	16.7% 1/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	25.0% 1/4 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	4.3% 2/47 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/22 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	2.9% 2/69 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days
Musculoskeletal and connective tissue disorders Muscular weakness	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	20.0% 1/5 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/4 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	2.1% 1/47 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/22 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	1.4% 1/69 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days
Musculoskeletal and connective tissue disorders Musculoskeletal chest pain	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/5 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/4 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/47 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	33.3% 1/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	4.5% 1/22 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	1.4% 1/69 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days
Musculoskeletal and connective tissue disorders Myalgia	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/5 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	16.7% 1/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/4 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	2.1% 1/47 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/22 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	1.4% 1/69 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days
Musculoskeletal and connective tissue disorders Osteoarthritis	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	33.3% 1/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/5 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/4 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	2.1% 1/47 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/22 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	1.4% 1/69 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days
Musculoskeletal and connective tissue disorders Pain in extremity	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/5 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/4 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/47 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	16.7% 1/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	4.5% 1/22 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	1.4% 1/69 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days
Nervous system disorders Balance disorder	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	14.3% 1/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/5 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/4 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	2.1% 1/47 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/22 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	1.4% 1/69 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days
Nervous system disorders Dizziness	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	33.3% 1/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	20.0% 1/5 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/4 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	4.3% 2/47 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/22 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	2.9% 2/69 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days
Nervous system disorders Dysgeusia	33.3% 1/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/5 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/4 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	2.1% 1/47 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	16.7% 1/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	4.5% 1/22 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	2.9% 2/69 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days
Nervous system disorders Headache	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	14.3% 1/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/5 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/4 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	2.1% 1/47 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	33.3% 1/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	4.5% 1/22 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	2.9% 2/69 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days
Nervous system disorders Paraesthesia	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	33.3% 1/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	28.6% 2/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	14.3% 1/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/5 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	16.7% 1/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	25.0% 1/4 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	12.8% 6/47 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/22 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	8.7% 6/69 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days
Nervous system disorders Syncope	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/5 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/4 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/47 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	16.7% 1/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	4.5% 1/22 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	1.4% 1/69 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days
Psychiatric disorders Anxiety	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	20.0% 1/5 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	16.7% 1/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	50.0% 2/4 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	8.5% 4/47 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	16.7% 1/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	4.5% 1/22 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	7.2% 5/69 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days
Psychiatric disorders Confusional state	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	14.3% 1/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/5 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/4 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	2.1% 1/47 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/22 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	1.4% 1/69 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days
Psychiatric disorders Depression	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	14.3% 1/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/5 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/4 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	2.1% 1/47 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/22 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	1.4% 1/69 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days
Psychiatric disorders Insomnia	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	14.3% 1/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/5 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/4 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	2.1% 1/47 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	16.7% 1/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	4.5% 1/22 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	2.9% 2/69 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days
Renal and urinary disorders Dysuria	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	14.3% 1/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/5 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/4 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	2.1% 1/47 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/22 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	1.4% 1/69 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days
Renal and urinary disorders Renal failure	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	14.3% 1/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/5 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/4 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	2.1% 1/47 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/22 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	1.4% 1/69 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days
Reproductive system and breast disorders Vaginal haemorrhage	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/5 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/4 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/47 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	33.3% 1/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	4.5% 1/22 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	1.4% 1/69 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days
Respiratory, thoracic and mediastinal disorders Cough	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	33.3% 1/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	28.6% 2/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/5 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	33.3% 2/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	25.0% 1/4 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	12.8% 6/47 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	100.0% 1/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	33.3% 1/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	16.7% 1/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	13.6% 3/22 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	13.0% 9/69 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days
Respiratory, thoracic and mediastinal disorders Dyspnoea	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	66.7% 2/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/5 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	16.7% 1/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	25.0% 1/4 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	8.5% 4/47 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	100.0% 1/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	33.3% 1/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	16.7% 1/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	13.6% 3/22 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	10.1% 7/69 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days
Respiratory, thoracic and mediastinal disorders Dyspnoea exertional	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	20.0% 1/5 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/4 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	2.1% 1/47 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	16.7% 1/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	4.5% 1/22 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	2.9% 2/69 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days
Respiratory, thoracic and mediastinal disorders Haemoptysis	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	33.3% 1/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/5 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	25.0% 1/4 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	4.3% 2/47 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/22 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	2.9% 2/69 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days
Respiratory, thoracic and mediastinal disorders Oropharyngeal pain	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	14.3% 1/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/5 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/4 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	2.1% 1/47 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/22 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	1.4% 1/69 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days
Respiratory, thoracic and mediastinal disorders Pleural effusion	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/5 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/4 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/47 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	16.7% 1/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	4.5% 1/22 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	1.4% 1/69 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days
Respiratory, thoracic and mediastinal disorders Pneumonia aspiration	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	33.3% 1/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/5 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/4 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	2.1% 1/47 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/22 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	1.4% 1/69 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days
Skin and subcutaneous tissue disorders Alopecia	33.3% 1/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/5 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	16.7% 1/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/4 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	4.3% 2/47 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/22 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	2.9% 2/69 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days
Skin and subcutaneous tissue disorders Dry skin	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/5 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/4 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/47 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	33.3% 1/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	4.5% 1/22 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	1.4% 1/69 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days
Skin and subcutaneous tissue disorders Night sweats	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	33.3% 1/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/5 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/4 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	2.1% 1/47 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/22 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	1.4% 1/69 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days
Skin and subcutaneous tissue disorders Petechiae	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/5 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/4 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/47 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	33.3% 1/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	4.5% 1/22 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	1.4% 1/69 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days
Skin and subcutaneous tissue disorders Photosensitivity reaction	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/5 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	25.0% 1/4 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	2.1% 1/47 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/22 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	1.4% 1/69 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days
Skin and subcutaneous tissue disorders Urticaria	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/5 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/4 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/47 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	16.7% 1/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	4.5% 1/22 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	1.4% 1/69 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days
Vascular disorders Hot flush	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	14.3% 1/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/5 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/4 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	2.1% 1/47 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/22 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	1.4% 1/69 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days
Vascular disorders Hypertension	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	33.3% 1/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	14.3% 1/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/5 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	25.0% 1/4 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	6.4% 3/47 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	100.0% 1/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	4.5% 1/22 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	5.8% 4/69 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days
Vascular disorders Hypotension	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/5 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/4 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/47 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	33.3% 1/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	4.5% 1/22 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	1.4% 1/69 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days
Vascular disorders Intermittent claudication	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/5 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/4 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/47 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	16.7% 1/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	4.5% 1/22 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	1.4% 1/69 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days
Vascular disorders Lymphoedema	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	20.0% 1/5 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/4 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	2.1% 1/47 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/22 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	1.4% 1/69 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days
Vascular disorders Vascular compression	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	14.3% 1/7 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/5 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/4 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	2.1% 1/47 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/1 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/3 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/6 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	0.00% 0/22 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days	1.4% 1/69 • From the start date of trial medication up to 21 days after the last administration of BI 847325, up to 266 days

Additional Information

Boehringer Ingelheim, Call Center

Boehringer Ingelheim

Phone: 1-800-243-0127

Email: [email protected]

Results disclosure agreements

Principal investigator is a sponsor employee Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.
Publication restrictions are in place

Restriction type: OTHER